Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
BioDrugs
Erschienen in: BioDrugs 5/2007

01.09.2007 | Novel Therapeutic Strategies

Autologous Conditioned Serum in the Treatment of Orthopedic Diseases

The Orthokine® Therapy

verfasst von: Dr Peter Wehling, Carsten Moser, David Frisbie, C. Wayne McIlwraith, Christopher E. Kawcak, Ruediger Krauspe, Julio A. Reinecke

Erschienen in: BioDrugs | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

The common strategies for the treatment of patients with orthopedic diseases do not address the underlying pathogenesis. Several biologically based, local therapies aiming to influence the cytokine imbalance are either in development or in the initial stages of clinical use. A method based on exposure of blood leukocytes to pyrogenfree surfaces (e.g. glass spheres) elicits an accumulation of anti-inflammatory cytokines, including interleukin-1 receptor antagonist, and several growth factors, including insulin-like growth factor-1, platelet-derived growth factor, and transforming growth factor-β1, in the liquid blood phase. Based on these observations, a new therapy using cell-free, autologous conditioned serum (ACS) from the incubation of whole blood with glass spheres was developed. The injection of ACS into affected tissue (s) has shown clinical effectiveness and safety in animal models and studies, as well as in human clinical studies, for the treatment of osteoarthritis, lumbar stenosis, disc prolapse, and muscle injuries.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
2
Actovegin® and Traumeel® are complex biologic preparations and there is no generic name for the active ingredients.
 
Literatur
1.
Puett DW, Griffin MR. Published trials of nonmedicinal and noninvasive therapies for hip and knee osteoarthritis. Ann Intern Med 1994 Jul 15; 121 (2): 133–40PubMed
2.
Buckwalter JA, Lohmander S. Operative treatment of osteoarthrosis: current practice and future development. J Bone Joint Surg Am 1994 Sep; 76 (9): 1405–18PubMed
3.
Buckwalter JA, Mow VC, Ratcliffe A. Restoration of injured or degenerated articular cartilage. J Am Acad Orthop Surg 1994 Jul; 2 (4): 192–201PubMed
4.
Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991 Jul 11; 325 (2): 87–91PubMedCrossRef
5.
Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993 Sep; 36 (9): 1196–206PubMedCrossRef
6.
Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993 Jul; 32 (7): 595–600PubMedCrossRef
7.
March L, Irwig L, Schwarz J, et al. N of 1 trials comparing a non-steroidal antiinflammatory drug with paracetamol in osteoarthritis. BMJ 1994 Oct 22; 309 (6961): 1041–5; discussion 6PubMedCrossRef
8.
Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Apr 30; 343 (8905): 1075–8PubMedCrossRef
9.
Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Mar 26; 343 (8900): 769–72PubMedCrossRef
10.
Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients. BMJ 1995 Apr 1; 310 (6983): 817–8PubMedCrossRef
11.
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005 (2): CD005328
12.
Baltzer AWA. Adverse event profile of NSAID in the treatment of musculoskeletal disorders. Z Orthop Ihre Grenzgeb 2003; 141: Oa369–71
13.
Petrella RJ, Petrella M. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. J Rheumatol 2006 May; 33 (5): 951–6PubMed
14.
Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005 Apr 12; 172 (8): 1039–43PubMedCrossRef
15.
Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003 Dec 17; 290 (23): 3115–21PubMedCrossRef
16.
Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004 Mar; 86-A (3): 538–45
17.
Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005 (2): CD005321
18.
Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000 Dec; 2 (6): 459–65PubMed
19.
Fukui N, Purple CR, Sandeil LJ. Cell biology of osteoarthritis: the chondrocyte’s response to injury. Curr Rheumatol Rep 2001 Dec; 3 (6): 496–505PubMedCrossRef
20.
Polisson R. Innovative therapies in osteoarthritis. Curr Rheumatol Rep 2001 Dec; 3 (6): 489–95PubMedCrossRef
21.
Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991 Nov; 12 (11): 404–10PubMedCrossRef
22.
Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991 Apr 15; 77 (8): 1627–52PubMed
23.
Granowitz EV, Clark BD, Mancilla J, et al. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991 Aug 5; 266 (22): 14147–50PubMed
24.
Firestein GS, Berger AE, Tracey DE, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992 Aug 1; 149 (3): 1054–62PubMed
25.
Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27–55PubMedCrossRef
26.
Arend WP, Welgus HG, Thompson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990 May; 85 (5): 1694–7PubMedCrossRef
27.
28.
Arend WP, Malyak M, Smith Jr MF, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994 Nov 15; 153 (10): 4766–74PubMed
29.
Arend WP, Malyak M, Bigler CF, et al. The biological role of naturally-occurring cytokine inhibitors. Br J Rheumatol 1991; 30Suppl. 2: 49–52PubMed
30.
Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985 Jun; 134 (6): 3868–75PubMed
31.
Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994 Jun; 139: 71–8PubMedCrossRef
32.
Arend WP, Smith Jr MF, Janson RW, et al. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 1991 Sep 1; 147 (5): 1530–6PubMed
33.
Meijer H, Reinecke J, Becker C, et al. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003 Oct; 52 (10): 404–7PubMedCrossRef
34.
Frisbie DD, Kawcak CE, Werpy NM, et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290–6PubMedCrossRef
35.
Frisbie DD, Kawcak CE, Baxter GM, et al. Effects of 6alpha-methylprednisolone acetate on an equine osteochondral fragment exercise model. Am J Vet Res 1998 Dec; 59 (12): 1619–28PubMed
36.
Frisbie DD, Kawcak CE, Trotter GW, et al. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J 1997 Sep; 29 (5): 349–59PubMedCrossRef
37.
Kawcak CE, Frisbie DD, Trotter GW, et al. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. Am J Vet Res 1997 Oct; 58 (10): 1132–40PubMed
38.
Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002 Jan; 9 (1): 12–20PubMedCrossRef
39.
Frisbie DD, Kawcak CE, Werpy NM, et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007 Mar; 68 (3): 290–6PubMedCrossRef
40.
Wright-Carpenter T, Opolon P, Appell HJ, et al. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med 2004 Nov; 25 (8): 582–7PubMedCrossRef
41.
Wright-Carpenter T, Klein P, Schaferhoff P, et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004 Nov; 25 (8): 588–93PubMedCrossRef
42.
Lefaucheur JP, Sebille A. Muscle regeneration following injury can be modified in vivo by immune neutralization of basic fibroblast growth factor, transforming growth factor beta 1 or insulin-like growth factor I. J Neuroimmunol 1995 Mar; 57 (1-2): 85–91PubMedCrossRef
43.
Moser C, Baltzer AWA, Jansen SA, et al. Autologous conditioned serum (ACS) compared to HA and saline injections for the treatment of knee OA [abstract podium no. 330]. American Academy of Orthopaedic Surgeons 74th Annual Meeting; 2007 Feb 14–18; San Diego (CA).
44.
Bellamy N, Bell MJ, Goldsmith CH, et al. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 2005 Jun; 64 (6): 881–5PubMedCrossRef
45.
Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986 Aug; 29 (8): 1039–49PubMedCrossRef
46.
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957 Dec; 16 (4): 494–502PubMedCrossRef
47.
Becker C, Heidersdorf S, Drewlo S, et al. Efficacy of epidural perineural injection with autologus conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blinded, reference-controlled study. Spine 2007; 17: 1803–8CrossRef
48.
Theodoridis T, Krämer J. Interleukin-1 Rezeptorantagonist-Protein in “Injektionstherapie an der Wirbelsäule”. Stuttgart: Georg Thieme Verlag, 2006: 37–40
49.
Kraemer J, Ludwig J, Bickert U, et al. Lumbar epidural perineural injection: a new technique. Eur Spine J 1997; 6 (5): 357–61PubMedCrossRef
Metadaten
Titel
Autologous Conditioned Serum in the Treatment of Orthopedic Diseases
The Orthokine® Therapy
verfasst von
Dr Peter Wehling
Carsten Moser
David Frisbie
C. Wayne McIlwraith
Christopher E. Kawcak
Ruediger Krauspe
Julio A. Reinecke
Publikationsdatum
01.09.2007
Verlag
Springer International Publishing
Erschienen in
BioDrugs / Ausgabe 5/2007
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200721050-00004

Weitere Artikel der Ausgabe 5/2007

BioDrugs 5/2007 Zur Ausgabe

Adis Drug Profile

Rituximab in Rheumatoid Arthritis

Drug Development

Cutting-Edge Apoptosis-Based Therapeutics

Adis Drug Profile

Rituximab

Mechanisms and Targets

Selective Targeting of Cancer Stem Cells

Mechanisms and Targets

Melanin-Concentrating Hormone Receptor-1 Antagonists as Antiobesity Therapeutics

Adis Drug Profile

Rituximab in Rheumatoid Arthritis